trending Market Intelligence /marketintelligence/en/news-insights/trending/jf-a0udu6jszahtfhdnvbg2 content esgSubNav
In This List

Akebia Therapeutics prices offering to raise $89M

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Akebia Therapeutics prices offering to raise $89M

Akebia Therapeutics, Inc. priced its previously announced stock offering, looking to raise $89 million via the sale of 8.5 million shares at $10.50 each.

Morgan Stanley is acting as sole book-running manager for the Cambridge, Mass.-based biotechnology company's offering, expected to close by March 27.

The offering's underwriter has an option to buy an additional 1,275,000 shares.

Akebia plans to use the net proceeds for the continued clinical development and optimization of the vadadustat program, meant to treat anemia associated with chronic kidney disease.